A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910